Battery Longevity in Deep Brain Stimulation for Parkinson's Disease.

IF 1.9 4区医学 Q3 NEUROIMAGING

Stereotactic and Functional Neurosurgery Pub Date : 2025-05-19 DOI:10.1159/000544714

Forough Yazdanian, Alejandro Enriquez-Marulanda, Nima Dehmamy, Ali Mortezaei, Taimur Hassan, Jay L Shils, Ron L Alterman

{"title":"Battery Longevity in Deep Brain Stimulation for Parkinson's Disease.","authors":"Forough Yazdanian, Alejandro Enriquez-Marulanda, Nima Dehmamy, Ali Mortezaei, Taimur Hassan, Jay L Shils, Ron L Alterman","doi":"10.1159/000544714","DOIUrl":null,"url":null,"abstract":"Introduction: In patients receiving deep brain stimulation (DBS) therapy, the longevity of the implanted pulse generator (IPG) is influenced by multiple factors, including patient diagnosis, therapeutic target, neurostimulator type, number of implanted leads, and stimulation settings. Recent advancements in DBS technology include longer-lived batteries, both standard and rechargeable. This study assesses the estimated IPG longevity of Medtronic, inc. Percept™ PC neurostimulator in Parkinson's Disease (PD) and explores factors associated with IPG lifespan.Methods: Retrospective analysis of Percept™ devices in 31 PD patients who underwent bilateral DBS targeting either the internal globus pallidus or the subthalamic nucleus. The analysis included demographics, clinical information, stimulation settings, lead locations, and Total Effective Energy Delivered (TEED).Results: The median IPG longevity was 75.9 months (51.6-92.3). Among stimulation parameters, frequency demonstrated the strongest inverse correlation with longevity (r=-0.49, p < 0.01), followed by pulse width (r=-0.39, p < 0.01), TEED (r=-0.35, p = p < 0.01), current amplitude (r=-0.33, p < 0.01) and voltage (r=-0.25, p = 0.04), regardless of laterality. In STN-targeted patients, a significant association was observed between the Z-coordinate of the right lead and the presence of side effects (p = 0.04). Monopolar stimulation on the dominant side showed significantly longer IPG longevity compared to bipolar stimulation (80.6 vs 49.6 months, p = 0.01).Conclusion: Significant negative correlations were observed between longevity and various stimulation parameters regardless of laterality. Monopolar stimulation on the dominant side was associated with increased longevity.","PeriodicalId":22078,"journal":{"name":"Stereotactic and Functional Neurosurgery","volume":" ","pages":"1-18"},"PeriodicalIF":1.9000,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Stereotactic and Functional Neurosurgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000544714","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NEUROIMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: In patients receiving deep brain stimulation (DBS) therapy, the longevity of the implanted pulse generator (IPG) is influenced by multiple factors, including patient diagnosis, therapeutic target, neurostimulator type, number of implanted leads, and stimulation settings. Recent advancements in DBS technology include longer-lived batteries, both standard and rechargeable. This study assesses the estimated IPG longevity of Medtronic, inc. Percept™ PC neurostimulator in Parkinson's Disease (PD) and explores factors associated with IPG lifespan.

Methods: Retrospective analysis of Percept™ devices in 31 PD patients who underwent bilateral DBS targeting either the internal globus pallidus or the subthalamic nucleus. The analysis included demographics, clinical information, stimulation settings, lead locations, and Total Effective Energy Delivered (TEED).

Results: The median IPG longevity was 75.9 months (51.6-92.3). Among stimulation parameters, frequency demonstrated the strongest inverse correlation with longevity (r=-0.49, p < 0.01), followed by pulse width (r=-0.39, p < 0.01), TEED (r=-0.35, p = p < 0.01), current amplitude (r=-0.33, p < 0.01) and voltage (r=-0.25, p = 0.04), regardless of laterality. In STN-targeted patients, a significant association was observed between the Z-coordinate of the right lead and the presence of side effects (p = 0.04). Monopolar stimulation on the dominant side showed significantly longer IPG longevity compared to bipolar stimulation (80.6 vs 49.6 months, p = 0.01).

Conclusion: Significant negative correlations were observed between longevity and various stimulation parameters regardless of laterality. Monopolar stimulation on the dominant side was associated with increased longevity.

查看原文本刊更多论文

脑深部电刺激治疗帕金森病的电池寿命

在接受深部脑刺激（DBS）治疗的患者中，植入脉冲发生器（IPG）的寿命受到多种因素的影响，包括患者诊断、治疗靶点、神经刺激器类型、植入导联数量和刺激设置。DBS技术的最新进展包括标准和可充电电池寿命更长。本研究评估了美敦力公司估计的IPG寿命。感知™PC神经刺激剂用于帕金森病（PD），并探索与IPG寿命相关的因素。方法：回顾性分析31例PD患者的perception™装置，这些患者接受了针对内苍白球或丘底核的双侧DBS。分析包括人口统计、临床信息、刺激设置、导联位置和总有效能量输送（TEED）。结果：IPG的中位寿命为75.9个月（51.6-92.3个月）。在刺激参数中，频率与寿命负相关最强（r=-0.49, p < 0.01），其次是脉冲宽度（r=-0.39, p < 0.01）、TEED （r=-0.35, p = p < 0.01）、电流幅值（r=-0.33, p < 0.01）和电压（r=-0.25, p = 0.04），与侧向无关。在stn靶向患者中，右导联z坐标与副作用存在显著相关（p = 0.04）。与双极刺激相比，优势侧单极刺激的IPG寿命明显更长（80.6个月vs 49.6个月，p = 0.01）。结论：不同的刺激参数与寿命之间存在显著的负相关。优势侧单极刺激与延长寿命有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Stereotactic and Functional Neurosurgery 医学-神经成像

CiteScore

3.80

自引率

0.00%

发文量

审稿时长

3 months

期刊介绍： ''Stereotactic and Functional Neurosurgery'' provides a single source for the reader to keep abreast of developments in the most rapidly advancing subspecialty within neurosurgery. Technological advances in computer-assisted surgery, robotics, imaging and neurophysiology are being applied to clinical problems with ever-increasing rapidity in stereotaxis more than any other field, providing opportunities for new approaches to surgical and radiotherapeutic management of diseases of the brain, spinal cord, and spine. Issues feature advances in the use of deep-brain stimulation, imaging-guided techniques in stereotactic biopsy and craniotomy, stereotactic radiosurgery, and stereotactically implanted and guided radiotherapeutics and biologicals in the treatment of functional and movement disorders, brain tumors, and other diseases of the brain. Background information from basic science laboratories related to such clinical advances provides the reader with an overall perspective of this field. Proceedings and abstracts from many of the key international meetings furnish an overview of this specialty available nowhere else. ''Stereotactic and Functional Neurosurgery'' meets the information needs of both investigators and clinicians in this rapidly advancing field.